Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?

导出 OA

翻译打印收藏纠错

作者： Anna,Gidari ^[1] ; Samuele,Sabbatini ^[2] ; Sabrina,Bastianelli ^[1] ; Sara,Pierucci ^[1] ; Chiara,Busti ^[1] ; Elisabetta,Svizzeretto ^[1] ; Andrea,Tommasi ^[1] ; Carlo,Pallotto ^[1] ; Elisabetta,Schiaroli ^[1] ; Daniela,Francisci ^[1]

作者单位： Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, 06132 Perugia, Italy. ^[1] Department of Medicine and Surgery, Medical Microbiology Section, University of Perugia, 06123 Perugia, Italy. ^[2]

关键词 COVID-19 Omicron SARS-CoV-2 cilgavimab immunocompromised tixagevimab variant

主题词人类(Humans);疾病大流行(Pandemics);抗体, 单克隆(Antibodies, Monoclonal)

DOI 10.3390/v16030354

PMID 38543720

发布时间 2024-05-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交